Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205413,
        author = {Aayushi Mehta and Naman Bhindora and Jagir Patel and Nilam Joshi and Dr. Akruti Patel},
        title = {Circulating MicroRNA Synergistic Orchestrators of Drug Response in Metabolic Syndrome},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {9344-9350},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205413},
        abstract = {Metabolic syndrome (MetS) is a cluster of cardiometabolic risk factors — central obesity, hypertension, dyslipidemia and insulin resistance — that together raise risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression post-transcriptionally and circulate in biofluids in stable forms (exosomes, microvesicles, or protein-bound). This review examines circulating miRNA (c-miRNA) signatures in the pathogenesis of MetS and in the modulation of drug response through direct regulation of drug-metabolizing enzymes (DMEs), drug transporters, and drug targets. Definitions and mechanisms are described, c-miRNA signatures associated with MetS components are presented, mechanistic links between c-miRNAs and pharmacokinetics/pharmacodynamics (PK/PD) are examined, and synergistic interactions between c-miRNAs and commonly used therapeutics in MetS (statins, antihypertensives, antidiabetics, and anti-obesity drugs) are explored.},
        keywords = {Metabolic Syndrome, MicroRNAs, Synergism, Statins, Antihypertensives, Antidiabetics, Circulating miRNA, Drug Response},
        month = {June},
        }